Fig. 7From: Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapyOverall survival in patients with breast cancer related to the mRNA levels of FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, and CREBBP. The plot was considered significant if logrank was p < 0.05Back to article page